CY1115516T1 - Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα - Google Patents

Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα

Info

Publication number
CY1115516T1
CY1115516T1 CY20141100695T CY141100695T CY1115516T1 CY 1115516 T1 CY1115516 T1 CY 1115516T1 CY 20141100695 T CY20141100695 T CY 20141100695T CY 141100695 T CY141100695 T CY 141100695T CY 1115516 T1 CY1115516 T1 CY 1115516T1
Authority
CY
Cyprus
Prior art keywords
agent
pharmaceutical composition
steroidal anti
combination
antispasmodic
Prior art date
Application number
CY20141100695T
Other languages
English (en)
Inventor
Armenta María Elena García
Murillo Josefina Santos
Ochoa Víctor Guillermo Álvarez
Original Assignee
Pptm International S.À R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pptm International S.À R.L. filed Critical Pptm International S.À R.L.
Publication of CY1115516T1 publication Critical patent/CY1115516T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μία φαρμακευτική σύνθεση που περιλαμβάνει ένα συνεργικό συνδυασμό ενός αντισπασμωδικού παράγοντα, τέτοιου όπως η δραστική ουσία γκαμπαπεντίνη και ενός μη-στεροειδούς αντι-φλεγμονώδους παράγοντα, τέτοιου όπως η δραστική ουσία μελοξικάμη, που τυποποιούνται μέσα σε μία ενιαία μονάδα δοσολογίας στη στοματική χορήγηση, αφού η εν λόγω σύνθεση προορίζεται για τη θεραπεία του νευροπαθητικού πόνου που προκαλείται από διάφορες αιτιολογίες.
CY20141100695T 2007-05-21 2014-08-28 Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα CY1115516T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2007006091A MX2007006091A (es) 2007-05-21 2007-05-21 Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante.
EP08766675.6A EP2151237B1 (en) 2007-05-21 2008-05-19 Pharmaceutical composition combining a non-steroidal anti-inflammatory agent and an anticonvulsant agent

Publications (1)

Publication Number Publication Date
CY1115516T1 true CY1115516T1 (el) 2017-01-04

Family

ID=40032119

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100695T CY1115516T1 (el) 2007-05-21 2014-08-28 Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα

Country Status (12)

Country Link
EP (1) EP2151237B1 (el)
AR (1) AR066666A1 (el)
BR (1) BRPI0811629A2 (el)
CL (1) CL2008001477A1 (el)
CY (1) CY1115516T1 (el)
EC (1) ECSP099734A (el)
ES (1) ES2503540T3 (el)
GT (1) GT200900296A (el)
MX (1) MX2007006091A (el)
PL (1) PL2151237T3 (el)
UY (1) UY31097A1 (el)
WO (1) WO2008143489A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1103205A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab Ltda Composição farmacêutica oral e uso da composição farmacêutica oral
US10874626B2 (en) 2016-04-07 2020-12-29 Nevakar Inc. Formulation for use in a method of treatment of pain
CA3075414A1 (en) 2017-10-03 2019-04-11 Nevakar Inc. Acetaminophen-pregabalin combinations and methods of treating pain
EP3818981B1 (en) * 2018-07-04 2024-02-21 Amézcua Amézcua, Federico Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain
WO2020141546A1 (en) * 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
MX2019008467A (es) * 2019-07-16 2019-11-07 Federico Amezcua Amezcua Combinacion sinergica de s-ketorolaco y pregabalina en una composicion farmaceutica para el tratamiento del dolor neuropatico.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1011658T3 (da) * 1997-09-08 2006-04-03 Warner Lambert Co Analgesiske præparater, der omfatter antiepileptiske forbindelser, og fremgangsmåder til anvendelse af samme
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
EP1481673A4 (en) * 2002-02-05 2008-09-24 Ajinomoto Kk MEDICAL COMPOSITIONS WITH GABAPENTIN OR PREGABALINE AND N-TYPE CALCIUM CHANNEL ANTAGONIST
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
MXPA05011735A (es) * 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases

Also Published As

Publication number Publication date
UY31097A1 (es) 2008-11-28
AR066666A1 (es) 2009-09-02
PL2151237T3 (pl) 2014-11-28
EP2151237A4 (en) 2012-10-24
EP2151237B1 (en) 2014-07-09
CL2008001477A1 (es) 2009-03-20
BRPI0811629A2 (pt) 2014-11-11
WO2008143489A1 (es) 2008-11-27
EP2151237A1 (en) 2010-02-10
ECSP099734A (es) 2009-12-28
ES2503540T3 (es) 2014-10-07
GT200900296A (es) 2016-01-21
MX2007006091A (es) 2009-02-25

Similar Documents

Publication Publication Date Title
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
CY1121492T1 (el) Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης και πρεγκαμπαλινης ή γκαμπαπεντινης
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
AR109590A2 (es) Régimen posológico para inhibidores de comt
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
EA200801997A1 (ru) Новые соединения
BRPI0709581A8 (pt) compostos de bicicloeteroarila como moduladores de px27 e seu uso
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CR11418A (es) Trans-clomifeno para el sindrome metabolico
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
BRPI0720500A8 (pt) Preparação líquida transdérmica
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
EA200702280A1 (ru) Синергические комбинации
CL2009001150A1 (es) Compuestos derivados de n-(2-amino-fenil)-acrilamidas, inhibidor de la histona-desacetilasa (hdac); procedimiento de preparacion; composicion faramceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.